SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies.
Science
; 375(6582): 782-787, 2022 02 18.
Article
em En
| MEDLINE
| ID: mdl-35076281
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type-elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
4_TD
Base de dados:
MEDLINE
Assunto principal:
Reações Cruzadas
/
Anticorpos Neutralizantes
/
Glicoproteína da Espícula de Coronavírus
/
SARS-CoV-2
/
COVID-19
/
Anticorpos Antivirais
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Science
Ano de publicação:
2022
Tipo de documento:
Article